Researchers Identified New Target in Head and Neck Cancer
A study found that targeting the G6PD enzyme may help reactivate immune cells to fight head and neck tumors.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Do you believe early-stage lab discoveries should be treated as reliable potential medical treatments?
Scientists have discovered that the enzyme glucose-6-phosphate dehydrogenase (G6PD) plays a critical role in the exhaustion of immune T cells in head and neck squamous cell carcinoma. This metabolic finding suggests a new strategy to improve the effectiveness of current cancer immunotherapies.
Why it matters
Exhausted T cells often struggle to mount an effective defense against tumors, limiting the success of current treatments. By identifying how these cells rely on the G6PD pathway, researchers have uncovered a potential mechanism to restore immune function in cancer patients.
Researchers studied tumor tissue from two phase II trials involving the use of nivolumab and anti-interleukin-8 antibodies. While 17% to 23% of patients currently respond to checkpoint inhibitor immunotherapy, the study highlights how metabolic reprogramming impacts T cell exhaustion.
The players
Johns Hopkins Medicine
This academic medical center served as the primary site for the research and the phase II clinical trials used to collect tumor tissue samples.
The details
The research team at Johns Hopkins Medicine analyzed the metabolic machinery and surface markers of T cells within tumor samples to determine their functional states. Laboratory experiments confirmed that combining a G6PD inhibitor with an anti-PD-1 antibody successfully reactivated previously exhausted CD8+ T cells.
Timeline
The research findings were published on October 28, 2026.
The Big Picture
This discovery marks a shift in cancer immunology by moving from broad checkpoint inhibition to targeted metabolic manipulation. The research extends the understanding of limitations found in the clinical evaluation of anti-PD-1 antibody nivolumab by addressing the metabolic reasons for patient non-response.
This research is in early laboratory stages and does not currently impact clinical treatment routines or medication availability for patients. It provides a foundational scientific basis for potential future therapies that could one day increase the number of patients responsive to immunotherapy.
The takeaway
Understanding the metabolic drivers of cell exhaustion could lead to more effective future cancer treatments. Researchers are now focused on testing whether these metabolic interventions function effectively in living systems.
Further reading
For more on the latest research in the field, explore the Cancer section.
Live Poll
Do you believe early-stage lab discoveries should be treated as reliable potential medical treatments?
